Cargando…
Efficacy of Mycobacterium indicus pranii Immunotherapy as an Adjunct to Chemotherapy for Tuberculosis and Underlying Immune Responses in the Lung
BACKGROUND: The 9-month-long chemotherapy of tuberculosis often results in poor compliance and emergence of drug-resistant strains. So, improved therapeutic strategy is urgently needed. Immunotherapy could be beneficial for the effective management of the disease. Previously we showed the protective...
Autores principales: | Gupta, Ankan, Ahmad, Farhan J., Ahmad, Faiz, Gupta, Umesh D., Natarajan, Mohan, Katoch, Vishwamohan, Bhaskar, Sangeeta |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3406023/ https://www.ncbi.nlm.nih.gov/pubmed/22844392 http://dx.doi.org/10.1371/journal.pone.0039215 |
Ejemplares similares
-
Mycobacterium indicus pranii as stand-alone or adjunct immunotherapeutic in treatment of experimental animal tuberculosis
por: Faujdar, Jaya, et al.
Publicado: (2011) -
Autophagy induction by Mycobacterium indicus pranii promotes Mycobacterium tuberculosis clearance from RAW 264.7 macrophages
por: Singh, Bindu, et al.
Publicado: (2017) -
T cell responses to Mycobacterium indicus pranii immunotherapy and adjunctive glucocorticoid therapy in tuberculous pericarditis()
por: Steigler, Pia, et al.
Publicado: (2022) -
Efficacy and Safety of Mycobacterium indicus pranii as an adjunct therapy in Category II pulmonary tuberculosis in a randomized trial
por: Sharma, Surendra K., et al.
Publicado: (2017) -
Activation of Anti-Tumor Immune Response and Reduction of Regulatory T Cells with Mycobacterium indicus pranii (MIP) Therapy in Tumor Bearing Mice
por: Ahmad, Faiz, et al.
Publicado: (2011)